Zoheb B Kazi1, Ankit K Desai1, Kathryn L Berrier1, R Bradley Troxler2, Raymond Y Wang3, Omar A Abdul-Rahman4, Pranoot Tanpaiboon5, Nancy J Mendelsohn6, Eli Herskovitz7, David Kronn8, Michal Inbar-Feigenberg9, Catherine Ward-Melver10, Michelle Polan10, Punita Gupta11, Amy S Rosenberg12, Priya S Kishnani1. 1. Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA. 2. University of Alabama at Birmingham, Birmingham, Alabama, USA. 3. Division of Metabolic Disorders, Children's Hospital of Orange County, Orange, California, USA. 4. Division of Medical Genetics, Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi, USA. 5. Division of Genetics and Metabolism, Children's National Health System, Washington, DC, USA. 6. Genomics Medicine Program, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, USA. 7. Pediatric Endocrinology and Metabolism Unit, Soroka Medical Center, Beer Sheva, Israel. 8. Department of Pediatrics, New York Medical College, Valhalla, New York, USA. 9. Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. 10. Division of Medical Genetics, Akron Children's Hospital, Akron, Ohio, USA. 11. Division of Medical Genetics, Department of Pediatrics, St. Joseph's Regional Medical Center Genetics, Paterson, New Jersey, USA. 12. Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, US FDA, Bethesda, Maryland, USA.
Abstract
BACKGROUND: Cross-reactive immunological material-negative (CRIM-negative) infantile Pompe disease (IPD) patients develop an immune response against enzyme replacement therapy (ERT) with alglucosidase alfa that nullifies ERT efficacy. Prophylactic immune tolerance induction (ITI) with rituximab, methotrexate, and IVIG successfully prevents development of deleterious rhGAA IgG antibodies; however, safety, likelihood of success, and long-term efficacy of ITI in a larger cohort remain unknown. METHODS: Clinical data were analyzed for 19 CRIM-negative IPD patients who received ITI with rituximab, methotrexate, and IVIG in the ERT-naive setting (ERT+ITI) and compared to a historical cohort of 10 CRIM-negative IPD patients on ERT monotherapy. RESULTS: ITI was safely tolerated, although infections were reported in 4 patients. Fourteen (74%) ERT+ITI patients were alive, with a median age of 44.2 months at their final assessment. The eldest survivor was 103.9 months old, with 100.2 months of follow-up after initiation of ERT+ITI. Death (n = 5) occurred at a median age of 29.2 months and was unrelated to the administration of ITI. Fifteen patients either did not seroconvert (n = 8) or maintained low titers (n = 7; defined as titers of ≤6,400 throughout the course of ERT) following ERT+ITI. Only one patient developed high and sustained antibody titers (defined as titers of ≥51,200 at or beyond 6 months on ERT). Left ventricular mass index (LVMI) decreased from a median of 248.5 g/m2 at baseline to 76.8 g/m2 at a median time from ERT+ITI initiation to 59 weeks. ERT+ITI significantly improved overall survival (P = 0.001), eliminated/reduced antibodies at values of ≤6,400 at week 52 on ERT (P = 0.0004), and improved LVMI at week 52 on ERT (P = 0.02) when compared with ERT monotherapy. CONCLUSION: Evidence from this international cohort of CRIM-negative IPD patients further supports the safety, feasibility, and efficacy of ITI in the prevention of immune responses to ERT. TRIAL REGISTRATION: Clinicaltrials.gov NCT01665326. FUNDING: This research was supported in part by the Lysosomal Disease Network, a part of NIH Rare Diseases Clinical Research Network, and by a grant from Genzyme, a Sanofi company.
BACKGROUND: Cross-reactive immunological material-negative (CRIM-negative) infantile Pompe disease (IPD) patients develop an immune response against enzyme replacement therapy (ERT) with alglucosidase alfa that nullifies ERT efficacy. Prophylactic immune tolerance induction (ITI) with rituximab, methotrexate, and IVIG successfully prevents development of deleterious rhGAA IgG antibodies; however, safety, likelihood of success, and long-term efficacy of ITI in a larger cohort remain unknown. METHODS: Clinical data were analyzed for 19 CRIM-negative IPD patients who received ITI with rituximab, methotrexate, and IVIG in the ERT-naive setting (ERT+ITI) and compared to a historical cohort of 10 CRIM-negative IPD patients on ERT monotherapy. RESULTS:ITI was safely tolerated, although infections were reported in 4 patients. Fourteen (74%) ERT+ITIpatients were alive, with a median age of 44.2 months at their final assessment. The eldest survivor was 103.9 months old, with 100.2 months of follow-up after initiation of ERT+ITI. Death (n = 5) occurred at a median age of 29.2 months and was unrelated to the administration of ITI. Fifteen patients either did not seroconvert (n = 8) or maintained low titers (n = 7; defined as titers of ≤6,400 throughout the course of ERT) following ERT+ITI. Only one patient developed high and sustained antibody titers (defined as titers of ≥51,200 at or beyond 6 months on ERT). Left ventricular mass index (LVMI) decreased from a median of 248.5 g/m2 at baseline to 76.8 g/m2 at a median time from ERT+ITI initiation to 59 weeks. ERT+ITI significantly improved overall survival (P = 0.001), eliminated/reduced antibodies at values of ≤6,400 at week 52 on ERT (P = 0.0004), and improved LVMI at week 52 on ERT (P = 0.02) when compared with ERT monotherapy. CONCLUSION: Evidence from this international cohort of CRIM-negative IPD patients further supports the safety, feasibility, and efficacy of ITI in the prevention of immune responses to ERT. TRIAL REGISTRATION: Clinicaltrials.gov NCT01665326. FUNDING: This research was supported in part by the Lysosomal Disease Network, a part of NIH Rare Diseases Clinical Research Network, and by a grant from Genzyme, a Sanofi company.
Authors: Zoheb B Kazi; Sean N Prater; Joyce A Kobori; David Viskochil; Carrie Bailey; Renuka Gera; David W Stockton; Paul McIntosh; Amy S Rosenberg; Priya S Kishnani Journal: JCI Insight Date: 2016-07-21
Authors: M Wadhwa; A L Skog; C Bird; P Ragnhammar; M Lilljefors; R Gaines-Das; H Mellstedt; R Thorpe Journal: Clin Cancer Res Date: 1999-06 Impact factor: 12.531
Authors: Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: Deeksha S Bali; Jennifer L Goldstein; Suhrad Banugaria; Jian Dai; Joanne Mackey; Catherine Rehder; Priya S Kishnani Journal: Am J Med Genet C Semin Med Genet Date: 2012-01-17 Impact factor: 3.908
Authors: Melissa E Elder; Sushrusha Nayak; Shelley W Collins; Lee Ann Lawson; Jeffry S Kelley; Roland W Herzog; Renee F Modica; Judy Lew; Robert M Lawrence; Barry J Byrne Journal: J Pediatr Date: 2013-04-16 Impact factor: 4.406
Authors: Suhrad G Banugaria; Sean N Prater; Yiu-Ki Ng; Joyce A Kobori; Richard S Finkel; Roger L Ladda; Yuan-Tsong Chen; Amy S Rosenberg; Priya S Kishnani Journal: Genet Med Date: 2011-08 Impact factor: 8.822
Authors: Kathryn L Berrier; Zoheb B Kazi; Sean N Prater; Deeksha S Bali; Jennifer Goldstein; Mihaela C Stefanescu; Catherine W Rehder; Eleanor G Botha; Carolyn Ellaway; Kaustuv Bhattacharya; Anna Tylki-Szymanska; Nesrin Karabul; Amy S Rosenberg; Priya S Kishnani Journal: Genet Med Date: 2015-03-05 Impact factor: 8.822
Authors: A S De Groot; Z B Kazi; R F Martin; F E Terry; A K Desai; W D Martin; P S Kishnani Journal: Clin Immunol Date: 2019-01-31 Impact factor: 3.969
Authors: Allison M Keeler; Marina Zieger; Sophia H Todeasa; Angela L McCall; Jennifer C Gifford; Samantha Birsak; Sourav R Choudhury; Barry J Byrne; Miguel Sena-Esteves; Mai K ElMallah Journal: Hum Gene Ther Date: 2018-07-25 Impact factor: 5.695
Authors: Mai K ElMallah; Ankit K Desai; Erica B Nading; Stephanie DeArmey; Richard M Kravitz; Priya S Kishnani Journal: Pediatr Pulmonol Date: 2020-01-03
Authors: Anne S De Groot; Ankit K Desai; Sandra Lelias; S M Shahjahan Miah; Frances E Terry; Sundos Khan; Cindy Li; John S Yi; Matt Ardito; William D Martin; Priya S Kishnani Journal: Front Immunol Date: 2021-06-16 Impact factor: 7.561